IP Library › Patent Application 11887105
Patent Application
App. No. 11/887,105

Treatment of asthma

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/887,105
Abstract

Substance P or its analogs are useful for treating asthma. The active agents can be administered orally, intravenously, intramuscularly, intranasally, topically. Disease severity is reduced by substance P treatment.

Claims (21)

1 . A method of treating an asthma patient, comprising:

administering to an asthma patient, an agent selected from the group consisting of: substance P, [Met-OH 11 ]-substance P, [Met-OMe 11 ]-substance P, [Nle 11 ]-substance P, [Pro 9 ]-substance P, [Sar 9 ]-substance P, [Tyr 8 ]-substance P, Sar 9 , Met (0 2 ) 11-Substance P, and [p-Cl-Phe 7,8 ]-substance P, whereby severity of symptoms of asthma in the patient is decreased.

2 . The method of claim 1 whereby inflammation in the lung is reduced.

3 . The method of claim 1 whereby inflammation in the airways is reduced.

4 . The method of claim 1 whereby poly(ADP-ribose) polymerase (PARP) activity in lung cells is inhibited.

5 . The method of claim 1 wherein poly(ADP-ribose) polymerase (PARP) expression in lung cells is inhibited.

6 . The method of claim 1 wherein the agent is administered as an aerosol to the airways.

7 . The method of claim 1 wherein the agent is administered orally.

8 . The method of claim 7 wherein the agent is administered in a time-release formulation.

9 . The method of claim 8 wherein the agent is released over a period of between 12 and 24 hours.

10 . The method of claim 1 wherein the agent is administered intravenously.

11 . The method of claim 1 wherein the agent is administered intramuscularly.

12 . The method of claim 1 wherein the agent is administered topically.

13 . The method of claim 1 wherein Sar 9 , Met (0 2 ) 11-Substance P is administered.

14 . The method of claim 1 wherein Substance P is administered.

15 . The method of claim 1 wherein [Met-OH 11 ]-substance P is administered.

16 . The method of claim 1 wherein [Met-OMe 11 ]-substance P is administered.

17 . The method of claim 1 wherein [Nle 11 ]-substance P is administered.

18 . The method of claim 1 wherein [Pro 9 ]-substance P is administered.

19 . The method of claim 1 wherein [Sar 9 ]-substance P is administered.

20 . The method of claim 1 wherein [Tyr 8 ]-substance P is administered.

Assignments (4)
PURCHASE AGREEMENT Recorded Sep 26, 2016
From: NEW EARTHSHELL CORP
To: WILHELM, MICHAEL
Reel/Frame 040150/0230 →
FIRST AMENDMENT TO SECURITY AGREEMENT Recorded Mar 11, 2010
From: IR BIOSCIENCES HOLDINGS, INC.; IMMUNEREGEN BIOSCIENCES, INC.
To: YA GLOBAL INVESTMENTS, L.P.
Reel/Frame 024055/0812 →
SECURITY AGREEMENT Recorded Aug 13, 2008
From: IR BIOSCIENCES HOLDINGS, INC.; IMMUNEREGEN BIOSCIENCES, INC.
To: YA GLOBAL INVESTMENTS, L.P.
Reel/Frame 021380/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2008
From: WITTEN, MARK L.
To: IMMUNEREGEN BIOSCIENCES, INC.
Reel/Frame 020881/0585 →